Consistent with the differences in the antitumor properties of different formulations, analyses of the peripheral blood cells demonstrated that mice treated with OVA@SVMAV had the highest percentage of CD69+ cells and OVA-specific cells among peripheral CD8+ T cells, which indicates robust CTL activation and clonal expansion targeting the tumor antigen with the induction of SVMAV in vivo (figure 4D, E and online supplemental figure S4A, B). This evidence concerns the gene CD8A and neoplasm.